no news_id given

Clinical Trial, GermanyGermany

01.02.2010

Apogenix GmbH (Heidelberg) has initiated a Phase II proof-of-concept study with its lead compound AGP101 + radiotherapy (vs radiotherapy alone) in 83 patients with Glioblastoma Multiforme (GBM). The clinical trial, which is...

Clinical Trial, UK

01.02.2010

Funxional Therapeutics Ltd (Cambridge, UK) has completed the Phase I programme of its anti-inflammatory compound FX125L, which belongs to the therapeutic class of Broad-Spectrum Chemokine Inhibitors (BSCIs). In its second safety...

Clinical Trial

01.02.2010

The EMA has finished its review of the benefits and risks of taking Biogen Idec and Elan’s multiple sclerosis drug natali­zumab (Tysabri) after 23 (14 EU, thereof 1 death) cases of potentially deadly brain infections with the JC...

Politics / Law

01.02.2010

London – The European Medicines Agency (formerly EMEA, now EMA) reported in January that it is adapting its organisational structure to its increasing workload and interactions with patient and consumer organisations. Human pre-...

Politics / Law

01.02.2010

GM rice looks set to arrive on plates in China within the next few years following a decision by the Chinese Agriculture Ministry’s bio­safety panel. Made up of 78 high-ranking experts, the panel has for the first time ever...

BioPeople

01.02.2010

Dr. Peter Heinrich has joined medical device company Magforce Nanotechnologies AG (Berlin) as Chief Executive Officer after former CEO Dr. Uwe Maschek chose to step down at the end of 2009. Heinrich co-founded MediGene AG, and...

BioPeople, UKUK

01.02.2010

Optos plc (London) has announced two changes in its management team. Dr. Peter Fellner has taken the helm at the retinal imaging company after Dr. John Padfield retired from his position as Chairman of the Board at the end of...

Miscellaneous

01.02.2010

Reykjavik – Icelandic gene-hunter deCode Genetics has emerged from bankruptcy and will continue its genetics research and gene-based diagnostics as a private company, but it will abandon its efforts to develop drugs from its...

Politics / Law, Denmark

01.02.2010

When the 2009 United Nations Climate Change Conference ended in December with the “Copenhagen Accord”, the final press release claims that the declaration “was supported by a majority of countries, including amongst them the...

BioPeople, Germany

01.02.2010

Frankfurt – Raupach & Wollert-Elmendorff is expanding into the life sciences sector. In January, the respected German advisors for business law announced they had hired Peter Homberg as an Equity Partner. Homberg is a renowned...

Displaying results 341 to 350 out of 1983

< Previous 341-350 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive/browse/34.html

Stock list

All quotes

TOP

  • FLAMEL TECHNOLOGIES (F)14.70 USD11.28%
  • SERODUS (N)3.05 NOK7.02%
  • ADDEX (CH)4.54 CHF5.83%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • NOVACYT (F)4.48 EUR-10.04%

TOP

  • SANTHERA (CH)70.65 CHF114.1%
  • ADDEX (CH)4.54 CHF108.3%
  • CELLECTIS (F)13.43 EUR102.0%

FLOP

  • THROMBOGENICS (B)8.67 EUR-51.3%
  • MERCK KGAA (D)63.67 EUR-50.6%
  • VERONA PHARMA (UK)1.20 GBP-43.4%

TOP

  • SANTHERA (CH)70.65 CHF3111.4%
  • GW PHARMACEUTICALS (UK)443.50 GBP843.6%
  • PAION (D)2.71 EUR310.6%

FLOP

  • CYTOS (CH)0.24 CHF-93.1%
  • EVOCUTIS (UK)0.21 GBP-92.6%
  • THROMBOGENICS (B)8.67 EUR-73.1%

No liability assumed, Date: 11.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events